| Name | Title | Contact Details |
|---|
North Shore P.R.N. is a Gloucester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MedPoint Communications, Inc is a Evanston, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Formativ Health is a management services organization that is redefining Practice Management and end-to-end Revenue Cycle through the integration of technology-enabled Patient Access, Revenue Cycle Management, Practice Operations and Advisory Services. At Formativ Health our approach is simple: We seek to understand your strategy and business goals so that we can define solutions tailored to your needs and designed to maximize performance. As the health care industry continues to transform, we partner with providers to successfully improve their financial health, adapt to changing risk-based payment models, increase physician productivity and satisfaction, and enhance the patient experience. Our technology-enabled services are designed to provide flexibility across the full continuum of Practice Management and Revenue Cycle
Essilor Canada Ltd. is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.